CYCN Korsana Biosciences, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
CYCN revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.76M, EPS -0.41
- Quarter ended Mar 31, 2026: revenue $0, net income −$3.18M, EPS -0.76
- Quarter ended Dec 31, 2025: revenue $1.03M, net income −$799K, EPS -0.14
- Quarter ended Sep 30, 2025: revenue $875K, net income −$976K, EPS -0.30
Recent CYCN insider trades
- Nov 21, 2024: Slate Path Capital LP sold 357,880 shares ($555K)
5%+ owners
- Tomas Kiselak: 20.0% (Schedule 13D, filed Sep 11, 2026)
- Peter M. Hecht: 19.4% (Schedule 13D/A, filed Jul 20, 2026)
- Venrock Healthcare Capital Partners III, L.P.: 9.9% (Schedule 13D, filed Sep 15, 2026)
- BALYASNY ASSET MANAGEMENT L.P.: 7.3% (Schedule 13G, filed Aug 14, 2026)
- ADAR1 Capital Management, LLC: 7.0% (Schedule 13G, filed Aug 14, 2026)
- FMR LLC: 6.9% (Schedule 13G/A, filed Oct 7, 2026)
Are insiders buying or selling CYCN?
No open-market insider buys or sells of Korsana Biosciences, Inc. were reported in the last 12 months.